top of page

NARA leads €1M round at MiMARK Diagnostics

The spin-off of the Vall d'Hebron Research Institute (VHIR), is NARA's fifth investee.

MiMARK Diagnostics, a spin-off of the Vall d'Hebron Research Institute (VHIR) specialized in the development of innovative solutions for gynaecological diagnosis based in the Barcelona Science Park, has raised €1 million that will allow it to accelerate the development of its in vitro diagnostic test for endometrial cancer WomEC, and start the development plan of its diagnostic test for endometrial cancer.

The operation has been led by the venture capital funds Nara Capital, Clave and Namarel Ventures, and the WA4Steam network of 'Business Angels' has also participated.

"This investment marks the beginning of a new stage for the company, with new challenges and challenges, and accompanies us on the way to achieve our goal; improve diagnosis in gynecology, making it a more accessible and less invasive diagnosis for women," explains Marina Rigau, CEO and co-founder of MiMARK Diagnostics. Rigau leads the femtech together with co-founders Antonio Gil-Moreno, head of the Biomedical Research in Gynecology group at VHIR and head of the Gynecology and Obstetrics service at Vall d'Hebron University Hospital, and Eva Colás, CSO of MiMARK and principal investigator in the same VHIR group.

Transforming gynecological diagnosis through gynecological fluids

MiMARK Diagnostics' mission is to transform gynecological diagnosis by focusing on the use of gynecological fluids as a source of biomarkers. "Gynecological fluids allow us to perform a minimally invasive approach to the diagnosis of gynecological diseases with unmet clinical needs, since these represent in a very specific way the adjacent tissues of gynecological organs," explains Eva Colás, CSO of MiMARK.

The company's first product and beneficiary of the investment is WomEC, an in vitro diagnostic test for endometrial cancer that is based on the analysis of proteins in the soluble fraction of a uterine aspirate sample. Endometrial cancer is the first gynecological cancer in developed countries, with more than 6,700 new cases per year in Spain. The diagnosis begins in women who have abnormal vaginal bleeding, although only 1 in 10 will have a diagnosis of endometrial cancer. Nowadays the diagnosis requires, in a large number of women, the performance of a biopsy guided by hysteroscopy, an invasive procedure that could be saved with WomEC.


bottom of page